サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1487515

慢性腎臓病（CKD）治療薬市場：世界の産業分析、規模、シェア、成長、動向、2024-2034年予測

Chronic Kidney Disease Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034
出版日: | 発行: Transparency Market Research | ページ情報: 英文 143 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.78円
慢性腎臓病（CKD）治療薬市場：世界の産業分析、規模、シェア、成長、動向、2024-2034年予測
出版日: 2024年04月05日
発行: Transparency Market Research
ページ情報: 英文 143 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

慢性腎臓病（CKD）治療薬市場- 調査範囲

TMRの調査レポート「世界の慢性腎臓病（CKD）治療薬市場」は、2024年から2034年までの予測期間における市場の指標に関する貴重な洞察を得るために、過去だけでなく現在の成長動向と機会についても調査しています。当レポートでは、2024年を基準年、2034年を予測年として、2018年から2034年までの世界の慢性腎臓病（CKD）治療薬市場の収益と予測を提供します。また、2024年から2034年までの世界の慢性腎臓病（CKD）治療薬市場の複合年間成長率（CAGR %）も掲載しています。

本レポートは広範な調査を経て作成されました。1次調査では、主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、慢性腎臓病（CKD）治療薬市場を理解するために、主要企業の製品資料、年次報告書、プレスリリース、関連文書を参照しました。

市場スナップショット
2023年の市場規模 148億米ドル
2034年の市場価値 238億米ドル
CAGR 4.2%

当レポートでは、世界の慢性腎臓病（CKD）治療薬市場の競合情勢について調査しています。世界の慢性腎臓病（CKD）治療薬市場で事業を展開する主要企業が特定され、各企業が様々な属性でプロファイルされています。企業概要、財務状況、最近の動向、およびSWOTは、本レポートで紹介されている世界の慢性腎臓病（CKD）治療薬市場におけるプレイヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 市場概要
  • 市場力学
  • 世界市場の分析と予測、2020-2034年

第5章 主要洞察

  • パイプライン分析
  • 主要製品/ブランド分析
  • 主要M&A
  • COVID-19パンデミックの業界への影響

第6章 世界市場分析と予測：薬剤クラス別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：薬剤クラス別, 2020-2034
    • ACE阻害薬
    • アンジオテンシンII受容体拮抗薬
    • カルシウム拮抗薬
    • β遮断薬
    • 赤血球造血刺激因子製剤（ESAs）
    • 利尿薬
    • その他
  • 市場魅力度分析：薬剤クラス別

第7章 世界市場分析・予測：エンドユーザー別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：エンドユーザー別、2020年～2034年
    • 病院
    • 専門クリニック
  • 市場魅力度分析：エンドユーザー別

第8章 世界市場分析・予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2020年～2034年
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力度分析：地域別

第9章 北米市場の分析と予測

第10章 欧州市場の分析と予測

第11章 アジア太平洋市場の分析と予測

第12章 ラテンアメリカ市場の分析と予測

第13章 中東・アフリカ市場の分析と予測

第14章 競合情勢

  • 市場競合マトリックス（企業階層別・企業規模別）
  • 市場シェア分析：企業別（2023年）
  • 企業プロファイル
    • F. Hoffmann-La Roche Ltd.
    • Pfizer, Inc.
    • Sanofi
    • GSK plc
    • Kissei Pharmaceutical Co., Ltd.
    • AbbVie Inc.
    • Akebia Therapeutics, Inc.
    • AstraZeneca
    • Amgen Inc.
    • Teva Pharmaceutical Industries Ltd.
図表

List of Tables

  • Table 01: Global Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
  • Table 02: Global Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 03: Global Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Region, 2020-2034
  • Table 04: North America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Country, 2020-2034
  • Table 05: North America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
  • Table 06: North America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 07: Europe Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 08: Europe Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
  • Table 09: Europe Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 10: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 11: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
  • Table 12: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 13: Latin America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 14: Latin America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
  • Table 15: Latin America Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2020-2034
  • Table 16: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
  • Table 17: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2020-2034
  • Table 18: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast, by End-user, 2020-2034

List of Figures

  • Figure 01: Global Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) and Distribution (%), by Region, 2023 and 2034
  • Figure 02: Global Chronic Kidney Disease (CKD) Drugs Market Revenue (US$ Mn), by Drug Class, 2023
  • Figure 03: Global Chronic Kidney Disease (CKD) Drugs Market Value Share, by Drug Class, 2023
  • Figure 04: Global Chronic Kidney Disease (CKD) Drugs Market Revenue (US$ Mn), by End-user, 2023
  • Figure 05: Global Chronic Kidney Disease (CKD) Drugs Market Value Share, by End-user, 2023
  • Figure 06: Global Chronic Kidney Disease (CKD) Drugs Market Value Share, by Region, 2023
  • Figure 07: Global Chronic Kidney Disease (CKD) Drugs Market Value (US$ Mn) Forecast, 2020-2034
  • Figure 08: Global Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 09: Global Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 10: Global Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 11: Global Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 12: Global Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Region, 2023 and 2034
  • Figure 13: Global Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Region, 2024-2034
  • Figure 14: North America Chronic Kidney Disease (CKD) Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 15: North America Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Country, 2024-2034
  • Figure 16: North America Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Country, 2023 and 2034
  • Figure 17: North America Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 18: North America Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 19: North America Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 20: North America Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 21: Europe Chronic Kidney Disease (CKD) Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 22: Europe Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 23: Europe Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 24: Europe Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 25: Europe Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 26: Europe Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 27: Europe Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 28: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 29: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 30: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 31: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 32: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 33: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 34: Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 35: Latin America Chronic Kidney Disease (CKD) Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 36: Latin America Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 37: Latin America Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 38: Latin America Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 39: Latin America Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 40: Latin America Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 41: Latin America Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by End-user, 2024-2034
  • Figure 42: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2020-2034
  • Figure 43: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
  • Figure 44: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
  • Figure 45: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by Drug Class, 2023 and 2034
  • Figure 46: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Value Share Analysis, by End-user, 2023 and 2034
  • Figure 47: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by Drug Class, 2024-2034
  • Figure 48: Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Attractiveness Analysis, by End-user, 2024-2034
目次
Product Code: TMRGL2481

Chronic Kidney Disease (CKD) Drugs Market - Scope of Report

TMR's report on the global chronic kidney disease (CKD) drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global chronic kidney disease (CKD) drugs market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global chronic kidney disease (CKD) drugs market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the chronic kidney disease (CKD) drugs market.

Market Snapshot
Market Value in 2023US$ 14.8 Bn
Market Value in 2034US$ 23.8 Bn
CAGR4.2%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global chronic kidney disease (CKD) drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global chronic kidney disease (CKD) drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global chronic kidney disease (CKD) drugs market.

The report delves into the competitive landscape of the global chronic kidney disease (CKD) drugs market. Key players operating in the global chronic kidney disease (CKD) drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global chronic kidney disease (CKD) drugs market profiled in this report.

Key Questions Answered in Global chronic kidney disease (CKD) drugs Market Report:

  • What is the sales/revenue generated by chronic kidney disease (CKD) drugs across all regions during the forecast period?
  • What are the opportunities in the global chronic kidney disease (CKD) drugs market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Chronic Kidney Disease (CKD) Drugs Market - Research Objectives and Research Approach

The comprehensive report on the global chronic kidney disease (CKD) drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global chronic kidney disease (CKD) drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global chronic kidney disease (CKD) drugs market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Chronic Kidney Disease (CKD) Drugs Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast, by Drug Class

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Class, 2020-2034
    • 6.3.1. ACE Inhibitors
    • 6.3.2. Angiotensin-II Receptor Blockers
    • 6.3.3. Calcium Channel Blockers
    • 6.3.4. Beta Blockers
    • 6.3.5. Erythropoiesis-stimulating Agents (ESAs)
    • 6.3.6. Diuretics
    • 6.3.7. Others
  • 6.4. Market Attractiveness Analysis, by Drug Class

7. Global Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast, by End-user

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by End-user, 2020-2034
    • 7.3.1. Hospitals
    • 7.3.2. Specialty Clinics
  • 7.4. Market Attractiveness Analysis, by End-user

8. Global Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region, 2020-2034
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness Analysis, by Region

9. North America Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast

  • 9.1. Introduction
  • 9.2. Key Findings
  • 9.3. Market Value Forecast, by Drug Class, 2020-2034
    • 9.3.1. ACE Inhibitors
    • 9.3.2. Angiotensin-II Receptor Blockers
    • 9.3.3. Calcium Channel Blockers
    • 9.3.4. Beta Blockers
    • 9.3.5. Erythropoiesis-stimulating Agents (ESAs)
    • 9.3.6. Diuretics
    • 9.3.7. Others
  • 9.4. Market Value Forecast, by End-user, 2020-2034
    • 9.4.1. Hospitals
    • 9.4.2. Specialty Clinics
  • 9.5. Market Value Forecast, by Country, 2020-2034
    • 9.5.1. U.S.
    • 9.5.2. Canada
  • 9.6. Market Attractiveness Analysis
    • 9.6.1. By Drug Class
    • 9.6.2. By End-user
    • 9.6.3. By Country

10. Europe Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Drug Class, 2020-2034
    • 10.3.1. ACE Inhibitors
    • 10.3.2. Angiotensin-II Receptor Blockers
    • 10.3.3. Calcium Channel Blockers
    • 10.3.4. Beta Blockers
    • 10.3.5. Erythropoiesis-stimulating Agents (ESAs)
    • 10.3.6. Diuretics
    • 10.3.7. Others
  • 10.4. Market Value Forecast, by End-user, 2020-2034
    • 10.4.1. Hospitals
    • 10.4.2. Specialty Clinics
  • 10.5. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 10.5.1. Germany
    • 10.5.2. U.K.
    • 10.5.3. France
    • 10.5.4. Italy
    • 10.5.5. Spain
    • 10.5.6. Rest of Europe
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Drug Class
    • 10.6.2. By End-user
    • 10.6.3. By Country/Sub-region

11. Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Drug Class, 2020-2034
    • 11.3.1. ACE Inhibitors
    • 11.3.2. Angiotensin-II Receptor Blockers
    • 11.3.3. Calcium Channel Blockers
    • 11.3.4. Beta Blockers
    • 11.3.5. Erythropoiesis-stimulating Agents (ESAs)
    • 11.3.6. Diuretics
    • 11.3.7. Others
  • 11.4. Market Value Forecast, by End-user, 2020-2034
    • 11.4.1. Hospitals
    • 11.4.2. Specialty Clinics
  • 11.5. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.5.1. China
    • 11.5.2. Japan
    • 11.5.3. India
    • 11.5.4. Australia & New Zealand
    • 11.5.5. Rest of Asia Pacific
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Drug Class
    • 11.6.2. By End-user
    • 11.6.3. By Country/Sub-region

12. Latin America Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Drug Class, 2020-2034
    • 12.3.1. ACE Inhibitors
    • 12.3.2. Angiotensin-II Receptor Blockers
    • 12.3.3. Calcium Channel Blockers
    • 12.3.4. Beta Blockers
    • 12.3.5. Erythropoiesis-stimulating Agents (ESAs)
    • 12.3.6. Diuretics
    • 12.3.7. Others
  • 12.4. Market Value Forecast, by End-user, 2020-2034
    • 12.4.1. Hospitals
    • 12.4.2. Specialty Clinics
  • 12.5. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.5.1. Brazil
    • 12.5.2. Mexico
    • 12.5.3. Rest of Latin America
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Drug Class
    • 12.6.2. By End-user
    • 12.6.3. By Country/Sub-region

13. Middle East & Africa Chronic Kidney Disease (CKD) Drugs Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Drug Class, 2020-2034
    • 13.3.1. ACE Inhibitors
    • 13.3.2. Angiotensin-II Receptor Blockers
    • 13.3.3. Calcium Channel Blockers
    • 13.3.4. Beta Blockers
    • 13.3.5. Erythropoiesis-stimulating Agents (ESAs)
    • 13.3.6. Diuretics
    • 13.3.7. Others
  • 13.4. Market Value Forecast, by End-user, 2020-2034
    • 13.4.1. Hospitals
    • 13.4.2. Specialty Clinics
  • 13.5. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.5.1. GCC Countries
    • 13.5.2. South Africa
    • 13.5.3. Rest of Middle East & Africa
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Drug Class
    • 13.6.2. By End-user
    • 13.6.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 14.2. Market Share Analysis, by Company (2023)
  • 14.3. Company Profiles
    • 14.3.1. F. Hoffmann-La Roche Ltd.
      • 14.3.1.1. Company Overview
      • 14.3.1.2. Product Portfolio
      • 14.3.1.3. SWOT Analysis
      • 14.3.1.4. Financial Overview
      • 14.3.1.5. Strategic Overview
    • 14.3.2. Pfizer, Inc.
      • 14.3.2.1. Company Overview
      • 14.3.2.2. Product Portfolio
      • 14.3.2.3. SWOT Analysis
      • 14.3.2.4. Financial Overview
      • 14.3.2.5. Strategic Overview
    • 14.3.3. Sanofi
      • 14.3.3.1. Company Overview
      • 14.3.3.2. Product Portfolio
      • 14.3.3.3. SWOT Analysis
      • 14.3.3.4. Financial Overview
      • 14.3.3.5. Strategic Overview
    • 14.3.4. GSK plc
      • 14.3.4.1. Company Overview
      • 14.3.4.2. Product Portfolio
      • 14.3.4.3. SWOT Analysis
      • 14.3.4.4. Financial Overview
      • 14.3.4.5. Strategic Overview
    • 14.3.5. Kissei Pharmaceutical Co., Ltd.
      • 14.3.5.1. Company Overview
      • 14.3.5.2. Product Portfolio
      • 14.3.5.3. SWOT Analysis
      • 14.3.5.4. Financial Overview
      • 14.3.5.5. Strategic Overview
    • 14.3.6. AbbVie Inc.
      • 14.3.6.1. Company Overview
      • 14.3.6.2. Product Portfolio
      • 14.3.6.3. SWOT Analysis
      • 14.3.6.4. Financial Overview
      • 14.3.6.5. Strategic Overview
    • 14.3.7. Akebia Therapeutics, Inc.
      • 14.3.7.1. Company Overview
      • 14.3.7.2. Product Portfolio
      • 14.3.7.3. SWOT Analysis
      • 14.3.7.4. Financial Overview
      • 14.3.7.5. Strategic Overview
    • 14.3.8. AstraZeneca
      • 14.3.8.1. Company Overview
      • 14.3.8.2. Product Portfolio
      • 14.3.8.3. SWOT Analysis
      • 14.3.8.4. Financial Overview
      • 14.3.8.5. Strategic Overview
    • 14.3.9. Amgen Inc.
      • 14.3.9.1. Company Overview
      • 14.3.9.2. Product Portfolio
      • 14.3.9.3. SWOT Analysis
      • 14.3.9.4. Financial Overview
      • 14.3.9.5. Strategic Overview
    • 14.3.10. Teva Pharmaceutical Industries Ltd.
      • 14.3.10.1. Company Overview
      • 14.3.10.2. Product Portfolio
      • 14.3.10.3. SWOT Analysis
      • 14.3.10.4. Financial Overview
      • 14.3.10.5. Strategic Overview